[Saralasin test in the differential diagnosis of essential and renal hypertension].
In a multicentric prospective study should be tested clinically the effectiveness and the tolerance of an angiotensin-II-antagonist (Saralasin-IWF) developed by the Institut für Wirkstofforschung der Akademie der Wissenschaften, its position in the differential-diagnostic step programme of the arterial hypertension should be analysed and with it should be performed pathogenetic investigations for hypertension after kidney transplantation. Taking into consideration international studies our results confirm that the Saralasin test, taking into account strongly standardized methodical prerequisites, is suited to objectify a participation of the RAAS in the hypertension pathogenesis, without, however, thus making an absolutely reliable evidence concerning the etiology of hypertension. The Saralasin test may represent an important diagnostic criterion for an optimization of the therapy of "volume-resistant" hypertension under the conditions of haemodialysis and in connection with selective renin determinations it possesses a high value in the screening diagnostics of the arterial stenosis after allogenic kidney transplantation.
D001794:Blood Pressure / Q000187:drug effects; D003937:Diagnosis, Differential; D006801:Humans; D006973:Hypertension / Q000175:diagnosis*; D006977:Hypertension, Renal / Q000175:diagnosis*; D006978:Hypertension, Renovascular / Q000175:diagnosis; D016030:Kidney Transplantation; D011183:Postoperative Complications / Q000175:diagnosis; D006435:Renal Dialysis; D012504:Saralasin
D012504:Saralasin
Der Saralasintest in der Differentialdiagnostik essentieller und renaler Hypertonien.